Roche's Xolair reduces reactions to severe food allergies in study

Xolair, a 20-year-old asthma drug sold by Roche (ROG.S) and Novartis (NOVN.S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting.